Aims-To determine the usefulness of antibodies HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of the pleura. Methods-Using microwave antigen retrieval and streptavidin-biotin complex horseradish peroxidase immunohistochemistry the above antibodies were used to stain sections of 57 malignant mesotheliomas, 17 reactive pleural hyperplasias, 23 cases of carcinoma metastatic in pleura, 20 primary ovarian cell carcinomas, and 20 primary renal cell carcinomas.
Distinguishing between malignant mesothelioma and metastatic carcinoma is a well recognised problem in surgical histopathology. A particular issue has been the lack of a specific marker for mesothelial cells in formalin fixed, paraffin wax embedded sections, although sev- eral reports have claimed variable success. '3 Many of the markers currently in routine use such as carcinoembryonic antigen (CEA),4
Leu Ml (CD15),4 8 and Ber-EP49 stain carcinomas, particularly adenocarcinoma, but not mesotheliomas, while epithelial membrane antigen (EMA)6 and human milk fat globulin 2 (HMFG-2)6 stain both, although perhaps in a different pattern. Malignant mesothelioma is, in practice, usually a diagnosis of exclusion rather than positive identification and the use of a panel of immunohistochemical markers is recommended,"0 " in addition to a mucin stain.
Antibodies to CEA are among the most useful in this area, staining carcinomas of tissues that derive embryologically from the foregut. However, ovarian and renal tubular epithelium have a similar embryological derivation to mesothelium and carcinomas of these tissues are often CEA negative.
Recently Immunohistochemistry was carried out using the streptavidin-biotin complex horseradish peroxidase (sABC HRP) method'3 with mouse monoclonal antibodies against HBME-1 (Dako M3505; High Wycombe, Bucks, UK), dilution 1/80, and antithrombomodulin (Dako M0617), dilution 1/10, using appropriate positive controls. The negative control for each case used Tris buffered saline.
Immunoreactivity was scored by two observers as negative (no immunostaining) or positive. Positive results were evaluated as strong or weak.
The percentage of immunostained cells in the population of interest was recorded as follows: + (focal, < 5% of cells); ++ (moderate, 5-70% of cells); +++ (widespread, > 70% of cells).
Results
The immunohistochemical results with HBME-1 and antithrombomodulin are shown in tables 1 and 2, respectively. No cases demonstrated weak staining in a widespread distribution (W+++).
HBME-1
Fifty three of 57 malignant mesotheliomas (93%) stained with HBME-1, 49 (86%) stained strongly and three quarters of those, 65% of the total, showed widespread staining. In 10 mesotheliomas with a sarcomatoid element, almost all of the sarcomatoid areas were negative or only weakly and/or focally positive, differing from the positive epithelioid regions in the three biphasic mesotheliomas. In these cases, the positivity of the epithelioid areas was recorded as the result. Sixteen out of 17 cases of reactive mesothelial hyperplasia (94%) stained with HBME-1, with a wide range of strength and number of cells positive; 14 of 17 (82%) showed strong staining, similar to the pattern seen in mesothelioma.
Twelve of 23 carcinomas metastatic to the pleura were negative with HBME-1, while the 11 positive cases (48%) showed a variable amount of strong staining. The metastases from primary lung tumours followed no particular staining pattern, and were as variable in their immunohistochemical staining results as the other metastatic carcinomas. Staining of the primary carcinomas from different sites was variable. All 10 of the serous cystadenocarcinomas of the ovary were strongly positive in a widespread distribution with HBME-1. Seven of the 10 mucinous cystadenocarcinomas of the ovary were negative but three cases demonstrated strong staining with a range of distribution. Nine of 10 renal clear cell carcinomas did not stain with HBME-1, but one case showed weak, focal positivity. Four of five renal carcinomas with a sarcomatoid pattern were negative but one case showed strong, moderate staining. The five renal carcinomas of papillary architecture also demonstrated a mixed result with three being negative and two showing degrees of positive staining.
ANTITHROMBOMODULIN
Forty nine of 57 malignant mesotheliomas (86%) stained with antithrombomodulin. As with HBME-1, the largest proportion (41 of 57, 72%) were strongly positive but the density of strongly stained cells was more variable, with the strong, moderate pattern being the most common (fig 1) . The sarcomatoid areas of the malignant mesotheliomas showed similar results to those seen with HBME-1; most did not stain. Nearly all cases of reactive mesothelial hyperplasia stained (15 of 17, 88%) with a range of positive cell density. None showed strong, widespread staining, compared to nine out of 17 (53%) cases staining strongly in a widespread distribution with HBME-1.
Overall, the carcinomas showed much less staining with antithrombomodulin than with HBME-1. Seventeen of the 23 metastatic carcinomas did not stain with antithrombomodulin. Those that did (six cases, 26%) were only focally positive (strong and weak staining).
All 10 ovarian serous cystadenocarcinomas were negative, as were nine of 10 mucinous HBME-1 and antithrombomodulin in the diagnosis of malignant mesothelioma ofpleura In 1992, the original report on HBME-1 Sheibani et al '4 described staining in majority of cases of epithelial-type malign mesothelioma, often with a membranous qi ity, and a few adenocarcinomas also shov staining. This painted an optimistic future HBME-1, but the lack of specificity mesothelioma has been documented in study and in several others,'5-'7 where up 72% of pulmonary adenocarcinomas w positive with HBME-1 ." Miettinen E Kovatich'5 also found ovarian serous carci mas to be positive consistently, but all re carcinomas that they studied were negative. These authors suggested, with some reservations, that HBME-1 would be useful in an antibody panel. We conclude, therefore, that although nal HBME-1 is sensitive at decorating benign and malignant mesothelial cells, it does not appear to be specific, because 44% of all carcinomas in this study stained positively. There is little use for HBME-1 as a marker in a panel of antibodies designed for the differential diagnosis of malignancy in the pleura. We consider that thrombomodulin is a useful marker for distinguishing malignant mesothelioma from carcinoma, given that it has an 86% sensitivity and only 13% of all carcinomas in this study stained; its usefulness is enhanced further by the fact that it does not significantly label tumours of organs with a similar embryological derivation to that of mesothelium that, potentially, might have expressed "mesothelial" markers. Antithrombomodulin is an appropriate antibody for use in an immunohistochemical panel as a "positive" mesothelial marker.
